Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Guggenhime also recently made the following trade(s):

• On Friday, October 18th, Andrew Guggenhime sold 42,000 shares of Vaxcyte stock. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00.

Vaxcyte Price Performance

Vaxcyte stock traded up $0.46 during mid-day trading on Thursday, hitting $86.21. The company’s stock had a trading volume of 1,143,054 shares, compared to its average volume of 908,236. The business has a 50 day moving average price of $99.77 and a 200-day moving average price of $92.07. Vaxcyte, Inc. has a 12 month low of $53.83 and a 12 month high of $121.06. The stock has a market cap of $10.74 billion, a price-to-earnings ratio of -18.74 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the firm earned ($0.91) EPS. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vaxcyte by 68.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after acquiring an additional 8,685 shares during the period. Natixis Advisors LLC raised its holdings in Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock worth $2,594,000 after purchasing an additional 8,606 shares in the last quarter. Tri Locum Partners LP bought a new stake in shares of Vaxcyte during the 2nd quarter valued at $8,559,000. Hsbc Holdings PLC purchased a new stake in shares of Vaxcyte in the 2nd quarter worth about $1,053,000. Finally, Lisanti Capital Growth LLC increased its stake in shares of Vaxcyte by 68.1% in the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after acquiring an additional 13,175 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on PCVX shares. Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Leerink Partners boosted their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Mizuho increased their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Jefferies Financial Group lifted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Bank of America increased their target price on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.